British re­searchers be­hind RE­COV­ERY re­turn for mon­key­pox drug study, launch­ing ahead of NIH tri­al

The UK-based Ox­ford Uni­ver­si­ty re­searchers be­hind the suc­cess­ful Covid-19 treat­ment tri­al RE­COV­ERY are back again, this time cob­bling to­geth­er a ran­dom­ized con­trolled tri­al to see if Siga Tech­nolo­gies’ small­pox treat­ment Tpoxx (tecovir­i­mat) is safe and ef­fec­tive for mon­key­pox.

The first par­tic­i­pant en­rolled on Fri­day in the PLAT­INUM (Place­bo-con­trolled ran­dom­ized tri­al of tecovir­i­mat in non­hos­pi­talised mon­key­pox pa­tients) tri­al, build­ing off an­i­mal mod­el suc­cess­es that led to FDA and UK ap­provals, and fol­lows the NIH’s Na­tion­al In­sti­tute of Al­ler­gy and In­fec­tious Dis­eases an­nounce­ment that it’s launch­ing a sim­i­lar tri­al in the US next week.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER